Address: Via Giovanni da Procida 11, 20149 Milano,Italy
Tel: +39 02 34565306
Web: http://assobiotec.federchimica.it/
Set up in October 1986 within the Italian Federation of the Chemical Industry (Federchimica), Assobiotec is the Italian Association for the Development of Biotechnology, representing more than 120 companies and science & technology parks operating in Italy and involved in various biotech-related fields – pharmaceuticals, diagnostics, agro-food, fine chemicals, environment, processing industry and equipment. They include emerging biotech companies and small to medium enterprises, as well as the biotech divisions of large organisations.
Assobiotec is co-founder member of EuropaBio, the European Association for Bioindustries, created in 1996.
Assobiotec provides entrepreneurial support to Italian and EU biotech developments and is the landmark for Italian companies involved in production and marketing of products derived from biotech applications.
Assobiotec focuses its main attention on:
regulatory issues affecting production, marketing and use of biotechnology products and their standards harmonisation;
fiscal and financial policies aimed at motivating industrial innovation;
R&D, education and training projects and programmes.
Assobiotec’s policy is mainly dealing with:
monitoring legislation in the regulatory area;
representing Italian bioindustry at National and international level;
providing a regular forum for the exchange of information and initiatives of entrepreneurial relevance;
taking active part to the reviewing process concerning the rules on industrial property.
Assobiotec’s activities include:
close interaction with National and international trade organisations dealing with biotechnology;
regular contacts with Universities, fostering collaboration between academia and industry in research and education;
information services on commercial biotech applications, on patents and on R&D programmes implementation.
Assobiotec’s Leonardo Vingiani introduces the key trends shaping the Italian biotech ecosystem today, the steps that the country’s government have taken to foster life sciences innovation, and the areas in…
Leonardo Vingiani, Director of Assobiotec, discusses how the country’s biotech industry has evolved since 2009, what areas still need improving and the enormous progress which has been made in unlocking…
Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report…
The CEO of MSD Italy discusses the company’s promising pipeline, its plans to realize growth through the launch of innovative new drugs in 2016, the paths towards a sustainable healthcare…
The MD of the Spanish Chamber of Commerce in Italy takes stock of the prevailing business winds between the two countries as both economies complete their emergence from the shadow of…
Massimo Visentin, Country Leader for Pfizer Italy, discusses the company’s remarkable success in 2015, his hopes and ambitions for the new year, and the need of the industry and Pfizer…
Prof. Luigi Naldini, Director of TIGET, discusses the success of the institute and the groundbreaking partnerships it has formed with the pharmaceutical industry, as well as his ambitions for TIGET…
Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics…
Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently…
Chris Juliam, Managing Director for Takeda Italy, shares the strategy the company is pursuing in the country, the effects market-access issues are having on innovators and patients, and what new…
Prof. Manuela Battaglia (MB) and Prof. Lorenzo Piemonti (LP) discuss the positioning of the Diabetes Research Institute (DRI) within the San Raffaele Scientific Institute and the global diabetes care community,…
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Enrique Hausermann, CEO of EG, the Stada Group’s Italian affiliate for its generics business, discusses the progress the company has made since 2009, the promising areas for growth he sees…
CFCII’s Director provides us with an overview of the services offered to French and Italian companies by the Chamber, as well as her perceptions about investments between the two countries,…
Alberto Gugliemo, President of the Carlo Besta Institute in Milan, shares the changing perception of neurological diseases and neurological science in Italy, the nature of the institute’s collaboration with the…
See our Cookie Privacy Policy Here
